Sebastian Sneha Annie, Kaiwan Oroshay, Co Edzel L, Mehendale Meghana, Mohan Babu P
Department of Internal Medicine Edgemont Medical Centre, Calgary, Canada.
Department of Medicine Northeast Ohio Medical University, USA.
Spartan Med Res J. 2024 Sep 9;9(3):123397. doi: 10.51894/001c.123397. eCollection 2024.
Ulcerative colitis (UC) is a chronic inflammatory bowel disorder (IBD) with periods of relapse and remission. Current advancements in clinical research have led to the development of more refined and effective medical therapy for UC.
Traditional therapeutic agents such as 5-aminosalicylates (5-ASAs), sulfasalazine (SASP), corticosteroids, and immunomodulatory drugs have remained the gold standard for decades. However, their novel formulations and dosage regimens have changed their sequences in the medical management of UC. Several other novel drugs are in the final phases of clinical development or have recently received regulatory approval designed to target specific mechanisms involved in the inflammatory cascade for UC.
This narrative review sought to provide a comprehensive knowledge of the potential benefits of standard and emerging therapies, including novel formulations, new chemical entities, and novel therapeutic approaches in managing UC. Keywords: Ulcerative colitis, 5- Aminosalicylic acid, sulfasalazine, corticosteroids, biologics, immunomodulators, novel formulations.
溃疡性结肠炎（UC）是一种慢性炎症性肠病（IBD），有复发和缓解期。临床研究的当前进展已导致开发出更精细、有效的UC医学疗法。
传统治疗药物，如5-氨基水杨酸酯（5-ASA）、柳氮磺胺吡啶（SASP）、皮质类固醇和免疫调节药物几十年来一直是金标准。然而，它们的新型制剂和给药方案改变了它们在UC医学管理中的顺序。其他几种新型药物正处于临床开发的最后阶段，或最近已获得监管批准，旨在针对UC炎症级联反应中涉及的特定机制。
本叙述性综述旨在全面介绍标准疗法和新兴疗法的潜在益处，包括新型制剂、新化学实体以及管理UC的新型治疗方法。关键词：溃疡性结肠炎、5-氨基水杨酸、柳氮磺胺吡啶、皮质类固醇、生物制剂、免疫调节剂、新型制剂。
